158 related articles for article (PubMed ID: 32708825)
1. ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.
Palshof JA; Cederbye CN; Høgdall EVS; Poulsen TS; Linnemann D; Nygaard SB; Stenvang J; Christensen IJ; Jensen BV; Pfeiffer P; Brünner N; Yilmaz M; Viuff BM; Nielsen DL
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708825
[TBL] [Abstract][Full Text] [Related]
2. CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Silvestris N; Simone G; Partipilo G; Scarpi E; Lorusso V; Brunetti AE; Maiello E; Paradiso A; Mangia A
Int J Mol Sci; 2014 Sep; 15(9):15767-77. PubMed ID: 25198900
[TBL] [Abstract][Full Text] [Related]
3. Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.
Nielsen DL; Palshof JA; Brünner N; Stenvang J; Viuff BM
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28880238
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
5. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
6. Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Shaojun C; Li H; Haixin H; Guisheng L
Cancer Biol Ther; 2018 Mar; 19(3):153-159. PubMed ID: 29261002
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab enhances the efficiency of irinotecan through simultaneously inhibiting the MAPK signaling and ABCG2 in colorectal cancer cells.
Ge XJ; Jiang JY; Wang M; Li MY; Zheng LM; Feng ZX; Liu L
Pathol Res Pract; 2020 Feb; 216(2):152798. PubMed ID: 31889589
[TBL] [Abstract][Full Text] [Related]
8. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
9. Association Between ABCG2, ABCB1, ABCC2 Efflux Transporter Single-Nucleotide Variants and Irinotecan Adverse Effects in Patients With Colorectal Cancer: A Real-Life Study.
Barnett-Griness O; Rennert G; Lejbkowicz F; Pinchev M; Saliba W; Gronich N
Clin Pharmacol Ther; 2023 Mar; 113(3):704-711. PubMed ID: 36537755
[TBL] [Abstract][Full Text] [Related]
10. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
11. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.
Kang D; Park JM; Jung CK; Lee BI; Oh ST; Choi MG
Cancer Biol Ther; 2015; 16(10):1438-44. PubMed ID: 26176272
[TBL] [Abstract][Full Text] [Related]
13. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
14. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy with 5-aminolaevulinic acid and DNA damage: unravelling roles of p53 and ABCG2.
Postiglione I; Barra F; Aloj SM; Palumbo G
Cell Prolif; 2016 Aug; 49(4):523-38. PubMed ID: 27389299
[TBL] [Abstract][Full Text] [Related]
16. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Cremolini C; Lonardi S; Bergamo F; Ning Y; Yamamoto N; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Stintzing S; Heinemann V; Loupakis F; Falcone A; Lenz HJ
Pharmacogenomics J; 2018 Sep; 18(5):623-632. PubMed ID: 29925895
[TBL] [Abstract][Full Text] [Related]
17. Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
Lin PC; Lin HH; Lin JK; Lin CC; Yang SH; Li AF; Chen WS; Chang SC
Int J Biol Markers; 2013 Jun; 28(2):182-6. PubMed ID: 23558935
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
19. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
To KK; Leung WW; Ng SS
Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
[TBL] [Abstract][Full Text] [Related]
20. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
